A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to see if it is safe to give tucaresol to HIV-infected patients who are taking combination anti-HIV therapy (HAART). This study also examines the effect tucaresol has on viral load (level of HIV in the body) when tucaresol is used with HAART.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients are enrolled sequentially into the next available dosage cohort. Each cohort receives a single dose of tucaresol, is observed for 2 weeks, and then receives 3 alternate-day doses of drug and careful safety monitoring, including 4 weeks follow-up after the final dose. Dose cohorts receive drug sequentially, the lowest-dose cohort receiving the drug first. Dose escalation may not proceed to the next higher-dose cohort until all patients from the prior lower-dose cohort have completed the 4-week follow-up after the multiple dosing, adverse events are within the described bounds, and the FDA has reviewed the safety information from the treated cohort and approved the dose escalation. The drug is administered 4 times within the 8 weeks of the study period. Weekly visits are required. Patients receive financial compensation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

HIV-1 Immunity, Cellular Drug Therapy, Combination CD4-Positive T-Lymphocytes Antigens Anti-HIV Agents Viral Load tucaresol

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tucaresol

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients may be eligible for this study if they:

* Are at least 18 years old.
* Are HIV-positive.
* Have more than 300 CD4 T cells/microL at screening.
* Are taking certain anti-HIV drugs.
* Have been taking these anti-HIV drugs successfully for at least 6 months.
* Do not expect to change their anti-HIV therapy while they are in the study.
* Have had plasma viral load less than 50 copies/ml while on their anti-HIV therapy.
* Have viral load that cannot be detected at screening and baseline tests.
* Are able to complete weekly visits.

Exclusion Criteria

Patients will not be eligible for this study if they:

* Cannot give informed consent.
* Have abnormal laboratory test results at baseline.
* Are pregnant or breast-feeding.
* Have had certain short-term or long-term illnesses (such as heart disease, sickle cell disease, anemia, or lung problems).
* Have received a vaccination within the 30 days prior to enrollment.
* Have received any other experimental drug within 60 days of enrollment.
* Are taking abacavir (Ziagen, GW1592) or drugs that affect the immune system, such as IL-2, GM-CSF, corticosteroids, or cyclosporine.
* Have a history of tumors.
* Are actively using illegal drugs (methadone is allowed).
* Have hepatitis B or hepatitis C.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rockefeller Univ

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

311A

Identifier Type: -

Identifier Source: org_study_id